JCJuan Manuel Calleja-Castillo

Juan Manuel Calleja-Castillo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Juan Manuel Calleja-Castillo has a total of 120 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Stroke Burden Attributable to Risk Factors in the Americas, 1990 to 2021: A Temporal Trends Analysis From the GBD Study 2021

    by Felipe Fregni, Bassel Almarie, Ramón Martinez, Verónica V. Olavarría, Carlos Abanto, Matias Alet, Tony Fabián Alvarez, Pablo Amaya, Sebastián F. Ameriso, Antonio Arauz, et al.

    Background: Stroke burden varies across the Americas, yet data on modifiable risk factor contributions remain limited. Methods: Using GBD (Global Burden of Disease) study 2021 data, we analyzed stroke mortality and disability‐adjusted life‐year (DALY) rates attributable to 23 modifiable risk factors across 39 countries and territories in the Americas. Age‐standardized rates were compared by sex, stroke subtype, region, and Socio‐Demographic Index; age‐specific estimates used 5‐year groups (25–95+ years). Trends were assessed using average annual percentage change (AAPC) from Joinpoint regression. Results: In 2021, 78.8% (95% uncertainty interval, 70.1%–85.9%) of stroke deaths and 76.9% (68.2%–83.6%) of DALYs were attributable to the 23 risk factors combined. High systolic blood pressure was the leading contributor, accounting for 20.87 attributable deaths (95% uncertainty interval, 15.17–25.80) and 453.30 DALYs (333.16–556.41) per 100 000, representing 54.8% of deaths and 52.2% of DALYs. From 1990 to 2021, the largest reductions occurred for household air pollution from solid fuels (deaths AAPC, −5.09% [95% CI, −5.17 to −5.02]; DALYs AAPC, −4.92% [−4.98 to −4.86]) and secondhand smoke (deaths AAPC, −3.45% [−3.49 to −3.41]). Reductions were minimal for high body mass index (deaths AAPC, −0.54% [−0.59 to −0.49]; DALYs AAPC, −0.42% [−0.46 to −0.37]), high fasting plasma glucose (deaths AAPC, −1.10% [−1.14 to −1.06]), and dietary risks; high body mass index burden increased in the Caribbean, notably in Haiti and the Dominican Republic. Stroke deaths attributable to high temperature increased >3.5% annually (AAPC) in Panama, Jamaica, and the Dominican Republic. High systolic blood pressure burden remained highly unequal, with age‐standardized death rates of 10.42 per 100 000 in high–Socio‐Demographic Index versus 109.33 in low–Socio‐Demographic Index countries. Conclusions: Stroke burden attributable to modifiable risk factors declined overall, but marked disparities persisted. High systolic blood pressure remained dominant, whereas stalled or increasing burden from obesity, metabolic, and dietary risks highlights the need for equity‐focused prevention across the Americas.

  • Open Access

    Challenges and Opportunities for Adult Vaccine Coverage: Insights for Healthcare Professionals Focusing on Herpes Zoster in Mexico

    by María Yolanda Cervantes-Apolinar, Adriana Guzman-Holst, Abiel Mascareñas De Los Santos, Alejandro Ernesto Macías Hernández, Álvaro Cabrera, Argelia Lara-Solares, Carlos Abud Mendoza, Daniel Motola Kuba, Diana Fabiola Flores Díaz, Fernanda Salgado Gomez, et al.

    Herpes zoster (HZ) is a common disease in older adults and immunocompromised patients, and is frequently associated with long-term complications that impact quality of life. Fortunately, more than one vaccine against HZ is now available in Mexico. Two expert consensus groups discussed adult vaccination strategies in Mexico, focusing on HZ in older adults and immunocompromised individuals; their insights are reported here. HZ is usually treated inappropriately in Mexico. Late diagnosis and suboptimal management are common, as is a lack of treatment options, particularly for pain, which is often unresponsive to standard painkillers. Improving vaccination rates against HZ in Mexico is therefore important, but several barriers to HZ vaccination exist. It is not included in the national vaccination schedule, where included vaccines usually have higher coverage. Actions to overcome barriers include improving awareness of HZ and vaccine availability, developing and promoting guidelines and recommendations for vaccination, and expanding access and infrastructure for vaccination.


  • Effect of size and location of unruptured intracranial aneurysms on self-reported headache

    by Juan Manuel Marquez-Romero, Dulce Anabel Espinoza-López, Juan Manuel Calleja-Castillo, Fernando Zermeño-Pohls, Rogelio Salinas-Gutiérrez

    AIM: To describe the relationship between aneurysm size and location with the prevalence of headache at diagnosis and three- and six-month follow-up in a sample of patients with UIA. MATERIAL and METHODS: In this cohort study, patients were diagnosed with UIAs by digital subtraction angiography (DSA). Follow-up visits occurred three and six months after the diagnosis. Headache presence was registered, and headache was further classified by phenotypes. After DSA, the recorded variables were aneurysm number, morphology, location, and size (diameter [W], neck [N], and dome-neck distance [H]). The aspect ratio (H/N) and the dome/neck ratio (W/N) were calculated. The outcome of this study was the self-reported headache status at follow-up. RESULTS: Data from 42 patients and 46 aneurysms were available; 81.0% of patients were women, with a mean age of 57.4 +/- 14.3 years. Headache was reported by 61.9% of the patients. The pain phenotype was tension-type in 38.1%, migraine in 11.9%, neuralgia in 2.4%, and unclassifiable in 9.5%. The median (min-max) measurements were W=5.05 (0.89-22.9); N=3.02 (0.52-17.9); H=5.08 (0.92-23.0); aspect ratio 1.59 (0.68-17.69) and W/N ratio 1.65 (0.62-16.92). Thirty-three patients (37 aneurysms) received treatment, 47.8% by surgical clipping and 32.6% by endovascular occlusion. In the treated patients, headaches had persisted in 14.3% until the first visit and in 9.5% until the second visit. There were no differences in any registered variables between patients with and without headaches at follow-up. CONCLUSION: In this study, data was found that support that headaches in patients with UIAs improve after treatment and that such improvement is probably unrelated to the size and shape of the UIAs.


  • Survival After Ischemic and Hemorrhagic Stroke: A 4-Year Follow-Up at a Mexican Hospital

    by Copytzy Cruz-Cruz, Hortensia Moreno-Macías, María del Socorro Parra-Cabrera, Carlos Hernández-Girón, Juan Manuel Calleja-Castillo


  • Open Access

    Opisthotonus (arc de cercle) in anti-NMDAR encephalitis

    by Guillermo Delgado-García, Vanessa Cano-Nigenda, Arturo Abundes-Corona, Karina Carrillo-Loza, Juan Calleja-Castillo, José Flores-Rivera

    A 21-year-old man presented with focal-onset seizures with evolution to bilateral tonic-clonic seizures, fever, and encephalopathy. In our hospital, he was diagnosed with anti-NMDAR encephalitis; this antibody was found to be positive in both serum and cerebrospinal fluid (CBA, IIFT, EUROIMMUN AG, Luebeck, Germany). Other causes of encephalitis were rationally excluded. During his hospital stay, he developed symptoms and signs compatible with catatonia. He was treated with high-dose methylprednisolone pulse therapy and therapeutic plasma exchange. Although he comparatively improved, days after finishing his fifth session of therapeutic plasma exchange, he developed a brief episode of opisthotonus (arc de cercle) (Figure), which resolved without any treatment. He had never had similar episodes in the past. This movement disorder is infrequently seen in contemporary clinical practice. In the 19th century, hysteria was one of the major differential diagnoses of episodic opisthotonus.


  • Open Access

    WhatsApp in Stroke Systems: Current Use and Regulatory Concerns

    by Juan M. Calleja-Castillo, Gina Gonzalez-Calderon

    Smartphone use is extremely common. Applications such as WhatsApp have billions of users and physicians are no exception. Stroke Medicine is a field where instant communication among fairly large groups is essential. In developing countries, economic limitations preclude the possibility of acquiring proper communication platforms. Thus, WhatsApp has been used as an organizational tool, for sharing clinical data, and for real time guidance of clinical care decisions. It has evolved into a cheap, accessible tool for telemedicine. Nevertheless, regulatory and privacy issues must be addressed. Some countries have implemented legislation to address this issue, while others lag behind. In this article, we present an overview on the different roles WhatsApp has acquired as a clinical tool in stroke systems and the potential privacy concerns of its use.


  • Open Access

    Exquisite response to intravenous immunoglobulin in Susac syndrome during pregnancy

    by Enrique Gomez-Figueroa, Sofia Garcia-Trejo, Raul Anwar Garcia-Santos, Gerardo Quiñones-Pesqueira, Juan Manuel Calleja-Castillo


  • Temporal Trends in Mortality from Ischemic and Hemorrhagic Stroke in Mexico, 1980-2012

    by Copytzy Cruz, Julio César Campuzano-Rincón, Juan Manuel Calleja-Castillo, Anaid Hernández-Álvarez, María del Socorro Parra, Hortensia Moreno-Macias, Carlos Hernández-Girón


  • Stroke in México: mortality trends 1980-2012

    by C. Cruz, C. Hernandez, S. Parra, J. Campuzano, J. Calleja, A. Hernandez

  • Time to recanalisation in patients with cerebral venous thrombosis under anticoagulation therapy

    by Antonio Arauz, Juan-Camilo Vargas-González, Nayelli Arguelles-Morales, Miguel A Barboza, Juan Calleja, Elizabeth Martínez-Jurado, Angélica Ruiz-Franco, Alejandro Quiroz-Compean, José G Merino

    Background and purpose Few studies have investigated the rates of recanalisation after cerebral venous thrombosis (CVT). Our objective was to investigate the recanalisation rate and to identify predictors of recanalisation in patients with CVT. Methods We included 102 patients with confirmed first-ever, non-septic CVT. All patients received anticoagulation for 12 months or until complete recanalisation. To assess recanalisation, patients underwent MR venography every 3 months until partial or complete recanalisation or for 12 months after diagnosis. We conducted two parallel analyses of complete recanalisation versus partial and no recanalisation versus any recanalisation. As a secondary objective we explored the influence of recanalisation on outcome and recurrent events. We calculated the probability of recanalisation using Kaplan-Meier analysis and conducted multivariate analysis using a Cox model. Results The mean age of patients was 33.5±11 years (80 (78.4%) women). Survival analysis indicated that 50% of the patients had any recanalisation (grades I, II and III) by 64 days and complete recanalisation (grade III) by 169 days. Adjusted Cox proportional model revealed that age Conclusions We found that recanalisation occurs over time, until month 11. Complete recanalisation may influence functional outcome.